FDA OMHHE Convener for Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH)
ID: 341723Type: Forecasted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Eligible Applicants

Small Businesses

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/341723
Timeline
    Description

    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "FDA OMHHE Convener for Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH)." This initiative aims to support a convener for the REACH consortium, which will consist of 5-8 multi-project cooperative agreement awardees focused on enhancing minority health and health equity through research, communication, and collaboration on diseases disproportionately affecting racial and ethnic minority populations. The selected convener will be responsible for coordinating data integration, analysis, and visualization, as well as facilitating workshops and collaborations among REACH investigators. Interested applicants, particularly small businesses, should note that there is no cost-sharing requirement, and the estimated synopsis post date is January 3, 2023, with a closing date of March 3, 2023. For further inquiries, contact Shashi Malhotra at shashi.malhotra@fda.hhs.gov or call 240-402-7592.

    Point(s) of Contact
    Shashi Malhotra Grants Management Specialist
    (240) 402-7592
    shashi.malhotra@fda.hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    FDA OMHHE Health Equity Innovation Award: Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH) (U01) Clinical Trials Optional
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the Health Equity Innovation Award: Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH), which will support cooperative agreements aimed at enhancing minority health and health equity research. This initiative seeks to establish a consortium of multiple recipients who will focus on advancing research, outreach, and communication efforts, while also providing training and mentoring for diverse students, fellows, and researchers. The program is crucial for addressing health disparities and promoting equity in healthcare access and outcomes among racial and ethnic minorities. Interested applicants can apply for a funding amount of $3 million, with an expected six awards to be made, and should contact Terrin Brown at terrin.brown@fda.hhs.gov or 240-402-7610 for further information. The opportunity is set for the fiscal year 2025.
    FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01)," aimed at advancing minority health and health equity objectives. This cooperative agreement seeks innovative research proposals that enhance diversity in clinical trials, improve data availability on diverse populations, and amplify diverse patient perspectives and needs. The initiative is crucial for addressing disparities in health outcomes and ensuring equitable representation in health research. Interested applicants can apply for a funding amount of $1 million, with an expected four awards to be made, and should direct inquiries to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610. The opportunity is set for the fiscal year 2025 and was last updated on August 14, 2024.
    FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering the Health Equity Innovation Award (U01) to fund innovative research aimed at enhancing minority health and advancing health equity objectives. This funding opportunity focuses on proposals that promote diversity in clinical trials, improve data availability on diverse populations, and amplify the voices of underrepresented patient groups. With an award ceiling of $1 million and a floor of $250,000, the FDA anticipates making four awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.
    Data Standards for Tobacco Research and Scientific Review Phase 2
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Data Standards for Tobacco Research and Scientific Review Phase 2," aimed at enhancing tobacco research and improving public health outcomes related to tobacco use. The primary objective of this initiative is to develop open, consensus-based data standards for studies on tobacco products, while also promoting education on standardized data usage among federal regulators, the tobacco industry, and global organizations. This funding opportunity, categorized under consumer protection, has an estimated total program funding of $400,000, with two awards expected to be granted. Interested applicants, particularly small businesses, should note that the synopsis is anticipated to be posted on October 1, 2023, with a closing date of December 1, 2023, and projects are expected to commence on May 1, 2024. For further inquiries, applicants can contact Rene A. Vasquez, Grants Management Specialist, at 301-796-3546 or via email at rene.vasquez@fda.hhs.gov.
    Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines." This initiative aims to support the dissemination of clinical practice guidelines, particularly those developed with prior FDA cooperative agreements, by requiring applicants to propose a comprehensive plan for developing, evaluating, and distributing materials that facilitate this dissemination, with a strong emphasis on equity. The funding for this opportunity has an award ceiling and floor of $1,000,000, with one award expected to be made in fiscal year 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further details.
    Rapid Response Team (RRT) Cooperative Agreement
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the Rapid Response Team (RRT) Cooperative Agreement, aimed at enhancing the national integrated food safety system. This initiative seeks to unify and coordinate emergency response efforts related to human and animal food (HAF), focusing on strengthening connections among epidemiology, laboratory, and regulatory components, as well as improving state regulatory and surveillance programs. The total estimated funding for this program is $8,250,000, with approximately 25 awards expected, and interested small businesses can reach out to Janelle Fundersburg at 301-798-2533 or via email at janelle.fundersburg@fda.hhs.gov for further details. The synopsis is anticipated to be posted on September 1, 2022, with a closing date for applications on December 1, 2022, and awards expected to be made by July 1, 2023.
    OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed." This cooperative agreement aims to enhance the FDA's Office of Minority Health and Health Equity (OMHHE) initiatives by promoting education, outreach, and public awareness regarding the use and potential risks associated with skin lightening products, such as hydroquinone. The funding is crucial for developing innovative, community-based strategies that will strengthen the scientific foundation for public health education on this topic. Interested applicants can apply for a funding amount of $250,000, with the opportunity forecasted for fiscal year 2025. For further inquiries, applicants may contact Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610.
    Center for Research on Complex Generics (U18) Clinical Trials Optional
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the establishment of a Center for Research on Complex Generics through a cooperative agreement. This initiative aims to enhance collaboration with the generic drug industry, focusing on identifying scientific challenges in generic product development and facilitating research that supports the FDA's mission to improve patient access to high-quality, safe, and effective generic drugs. The Center will serve as a hub for coordination among FDA, academia, and industry stakeholders, conducting research, hosting workshops, and providing public access to research outcomes. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610. The funding amount is set at $1.5 million, with one award anticipated for the fiscal year 2025.
    African Medical Devices Regulatory Harmonization Program
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled the African Medical Devices Regulatory Harmonization Program. This initiative aims to establish harmonized approaches, standards, and guidelines to enhance the innovation, development, regulation, and availability of medical devices that comply with quality and safety requirements across the African continent. Such efforts are vital to ensure consistent regulatory oversight and to mitigate the risks associated with poor-quality medical products, which can have significant health implications and financial burdens. Interested applicants can reach out to Shashi Malhotra, Grants Management Specialist, at shashi.malhotra@fda.hhs.gov or call 240-402-7592 for further information, with the program being part of the fiscal year 2023 funding cycle under CFDA number 93.103.
    OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a grant opportunity titled "OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed." This initiative aims to enhance the FDA's Office of Minority Health and Health Equity (OMHHE) efforts by funding research and community-based strategies that promote education and public awareness regarding the risks associated with over-the-counter skin lightening products containing hydroquinone and/or mercury. The grant, which has a fixed award amount of $250,000, is open to unrestricted applicants and is part of the fiscal year 2024 funding cycle. Interested parties can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.